Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets

[1]  M. Hargraves,et al.  The Children , 2020, Bring Now the Angels.

[2]  C. Filipe,et al.  Thermal Stabilization of Viral Vaccines in Low-Cost Sugar Films , 2019, Scientific Reports.

[3]  Henry A. Utset,et al.  Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. , 2019, Cell host & microbe.

[4]  W. Hinrichs,et al.  Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge , 2018, European Journal of Pharmaceutics and Biopharmaceutics.

[5]  W. Hinrichs,et al.  Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge , 2018, Journal of Controlled Release.

[6]  Diane J Post,et al.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases , 2018, The Journal of infectious diseases.

[7]  P. Kulkarni,et al.  Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study , 2018, Drug Safety.

[8]  J. Tregoning,et al.  Adjuvanted influenza vaccines , 2018, Human vaccines & immunotherapeutics.

[9]  A. Pekosz,et al.  The M2 protein of live, attenuated influenza vaccine encodes a mutation that reduces replication in human nasal epithelial cells. , 2017, Vaccine.

[10]  H. Frijlink,et al.  Developments in the formulation and delivery of spray dried vaccines , 2017, Human vaccines & immunotherapeutics.

[11]  N. Petrovsky,et al.  Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection , 2017, Scientific Reports.

[12]  Todd G. Smith,et al.  Assessment of the immunogenicity of rabies vaccine preserved by vaporization and delivered to the duodenal mucosa of gray foxes (Urocyon cinereoargenteus). , 2017, American journal of veterinary research.

[13]  Anna-Léa Kahn,et al.  Extending supply chains and improving immunization coverage and equity through controlled temperature chain use of vaccines. , 2017, Vaccine.

[14]  H. Yamada,et al.  Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines , 2016, EBioMedicine.

[15]  C. Ambrose,et al.  Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States. , 2016, Vaccine.

[16]  Timothy B. Stockwell,et al.  Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus , 2016, Journal of Virology.

[17]  N. Petrovsky,et al.  Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant , 2016, Vaccine.

[18]  P. Tambyah,et al.  Influenza infection in human host: challenges in making a better influenza vaccine , 2016, Expert review of anti-infective therapy.

[19]  T. De Beer,et al.  Freeze-drying of live virus vaccines: A review. , 2015, Vaccine.

[20]  N. Petrovsky.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs , 2015, Drug Safety.

[21]  N. Petrovsky,et al.  Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single–dose influenza vaccine protection , 2015, Vaccine.

[22]  N. Petrovsky,et al.  Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine , 2015, PloS one.

[23]  M. Tashiro,et al.  Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus , 2015, Proceedings of the National Academy of Sciences.

[24]  Todd G. Smith,et al.  Rabies vaccine preserved by vaporization is thermostable and immunogenic. , 2015, Vaccine.

[25]  S. Hugonnet,et al.  The development of global vaccine stockpiles. , 2015, The Lancet. Infectious diseases.

[26]  Jiyuan Tu,et al.  Measurements of droplet size distribution and analysis of nasal spray atomization from different actuation pressure. , 2015, Journal of aerosol medicine and pulmonary drug delivery.

[27]  Nikolai Petrovsky,et al.  Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. , 2014, Vaccine.

[28]  N. Petrovsky,et al.  A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection. , 2014, Vaccine.

[29]  H. Hasegawa,et al.  Mucosal Immunization and Adjuvants , 2014, Current topics in microbiology and immunology.

[30]  N. Petrovsky,et al.  Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant , 2014, Clinical and Vaccine Immunology.

[31]  H. Jin,et al.  A Single Amino Acid in the Stalk Region of the H1N1pdm Influenza Virus HA Protein Affects Viral Fusion, Stability and Infectivity , 2014, PLoS pathogens.

[32]  N. Petrovsky,et al.  An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody , 2013, Journal of Virology.

[33]  N. Petrovsky,et al.  JE-ADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8+ T Cells and Pre-Exposure Neutralizing Antibody , 2013, Journal of Virology.

[34]  P. Djupesland.  Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review , 2012, Drug Delivery and Translational Research.

[35]  Per Gisle Djupesland,et al.  Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review , 2012, Drug Delivery and Translational Research.

[36]  A. Skretting,et al.  Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. , 2012, Journal of aerosol medicine and pulmonary drug delivery.

[37]  Y. Kawaoka,et al.  Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium , 2012, Journal of Virology.

[38]  Nikolai Petrovsky,et al.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. , 2012, Vaccine.

[39]  N. Petrovsky,et al.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. , 2012, Vaccine.

[40]  Hanzhong Wang,et al.  Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge , 2012, Archives of Virology.

[41]  H. van den Bosch,et al.  Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. , 2011, Vaccine.

[42]  N. Petrovsky,et al.  Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. , 2011, Glycobiology.

[43]  A. Dyson,et al.  Challenges and possibilities , 2011 .

[44]  N. Petrovsky,et al.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses , 2010, The Journal of general virology.

[45]  P. Palese,et al.  Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. , 2009, Vaccine.

[46]  L. Hessel,et al.  Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges , 2009, Influenza and other respiratory viruses.

[47]  W. Gruber,et al.  Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children , 2008, Clinical and Vaccine Immunology.

[48]  W. Hinrichs,et al.  Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities , 2008, Pharmaceutical Research.

[49]  Yung-sung Cheng,et al.  The influence of spray properties on intranasal deposition. , 2007, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[50]  R. Walker,et al.  Comparative Immunogenicities of Frozen and Refrigerated Formulations of Live Attenuated Influenza Vaccine in Healthy Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[51]  H. Katinger,et al.  Live Attenuated Influenza Virus Expressing Human Interleukin-2 Reveals Increased Immunogenic Potential in Young and Aged Hosts , 2006, Journal of Virology.

[52]  Response,et al.  Global pandemic influenza action plan to increase vaccine supply , 2006 .

[53]  E. D. Kilbourne.  Influenza Pandemics of the 20th Century , 2006, Emerging infectious diseases.

[54]  J. Taubenberger,et al.  1918 Influenza: the Mother of All Pandemics , 2006, Emerging infectious diseases.

[55]  C. Bridges,et al.  Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[56]  G. Tannock,et al.  Immunogenic and isotype‐specific responses to russian and US cold‐adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice , 2001, Journal of medical virology.

[57]  W. Gruber,et al.  Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. , 1999 .

[58]  A. Hill,et al.  The Structure and Properties of Glassy Polymers: An Overview , 1999 .

[59]  A. Hill,et al.  Structure and properties of glassy polymers , 1999 .

[60]  B. Lampson,et al.  Protection 1 , 2022 .

[61]  B. Murphy,et al.  Reduced Infectivity of Cold‐Adapted Influenza A H1N1 Viruses in the Elderly: Correlation with Serum and Local Antibodies , 1992, Journal of the American Geriatrics Society.

[62]  B. Murphy,et al.  Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines , 1989, Journal of clinical microbiology.

[63]  H. Maassab,et al.  Adaptation and Growth Characteristics of Influenza Virus at 25° C , 1967, Nature.

[64]  T. Bahamondez-Canas,et al.  Intranasal immunization with dry powder vaccines , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[65]  Heinz Mehlhorn,et al.  World Organisation for Animal Health (OIE) , 2015 .

[66]  H. Greenberg,et al.  Live attenuated influenza vaccine , 2011 .

[67]  K. Subbarao,et al.  Live attenuated vaccines for pandemic influenza. , 2009, Current topics in microbiology and immunology.

[68]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[69]  H. Maassab,et al.  Adaptation and growth characteristics of influenza virus at 25 degrees c. , 1967, Nature.

[70]  G. Alexandrova,et al.  Obtaining of an Additionally Attenuated Vaccinating Cryophil Influenza Strain. , 1965 .

[71]  J. Taubenberger,et al.  Influenza : the Mother of All Pandemics , 2022 .